1. Home
  2. REGN vs SNOW Comparison

REGN vs SNOW Comparison

Compare REGN & SNOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$746.39

Market Cap

79.4B

Sector

Health Care

ML Signal

HOLD

Logo Snowflake Inc.

SNOW

Snowflake Inc.

HOLD

Current Price

$178.50

Market Cap

87.1B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
REGN
SNOW
Founded
1988
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
79.4B
87.1B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
REGN
SNOW
Price
$746.39
$178.50
Analyst Decision
Buy
Strong Buy
Analyst Count
24
44
Target Price
$819.54
$247.30
AVG Volume (30 Days)
559.3K
5.7M
Earning Date
01-01-0001
05-27-2026
Dividend Yield
0.50%
N/A
EPS Growth
8.19
N/A
EPS
41.48
N/A
Revenue
$5,872,227,000.00
$3,626,396,000.00
Revenue This Year
$11.69
$27.93
Revenue Next Year
$10.06
$23.00
P/E Ratio
$17.98
N/A
Revenue Growth
20.82
29.21
52 Week Low
$476.49
$120.10
52 Week High
$821.11
$280.67

Technical Indicators

Market Signals
Indicator
REGN
SNOW
Relative Strength Index (RSI) 42.37 49.47
Support Level $740.39 $155.35
Resistance Level $788.69 $225.26
Average True Range (ATR) 21.98 8.21
MACD -4.12 2.39
Stochastic Oscillator 6.97 79.28

Price Performance

Historical Comparison
REGN
SNOW

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About SNOW Snowflake Inc.

Founded in 2012, Snowflake is a fully managed platform that consolidates data hosted on different public clouds for centralized analytics and governance. Snowflake's cloud-native architecture allows users to independently scale the compute and storage layers, providing customers with optimized performance at lower costs. The company's data lake and data warehouse products support a variety of use cases, including business analytics, data engineering, and artificial intelligence. Snowflake is widely used by Fortune 2000 companies in financial services, media, and retail sectors.

Share on Social Networks: